Low-Dose of Intrapulmonary Pirfenidone Improves Human Transforming Growth Factorβ1-Driven Lung Fibrosis

• Main Authors: Tomohito Okano (Author), Tetsu Kobayashi (Author), Taro Yasuma (Author), Corina N. D'Alessandro-Gabazza (Author), Masaaki Toda (Author), Hajime Fujimoto (Author), Hiroki Nakahara (Author), Yuko Okano (Author), Atsuro Takeshita (Author), Kota Nishihama (Author), Haruko Saiki (Author), Atsushi Tomaru (Author), Valeria Fridman D'Alessandro (Author), Satoru Ishida (Author), Hiromi Sugimoto (Author), Yoshiyuki Takei (Author), Esteban C. Gabazza (Author)
• Format: Book
• Published: Frontiers Media S.A., 2020-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Idiopathic pulmonary fibrosis is a chronic, progressive, and lethal lung disease of unknown etiology. Antifibrotic drugs, including pirfenidone, are currently used for the treatment of the disease. The oral administration of pirfenidone is an effective therapy, as demonstrated by several clinical tr...